

AMENDMENT AND RESPONSE TO OFFICE ACTION

Amendment

In the Claims

1. (currently amended) A composition for the nasal administration of a drug in a dry powder form suitable for administration to the nasal region,

the dry powder form comprising microparticles having ~~an average a~~ particle size of between 10 microns and to 20 microns in diameter and comprising the drug and a diketopiperazines diketopiperazine.

2. (original) The composition of claim 1 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

3. (original) The composition of claim 2 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

4. (previously presented) The composition of claim 1 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.

5. (currently amended) The composition of claim 1 wherein the diketopiperazine diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.

6. (canceled)

7. (currently amended) A drug delivery device for nasal administration comprising a drug in a dry powder form in a dosage formulation for administration to the nasal region, and

U.S.S.N. 09/766,362

Filed: January 19, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

a device for delivering a measured dose of the drug to the nasal mucosa,
wherein the dry powder form comprises microparticles having an average a particle size
of between 10 microns and to 20 microns in diameter and comprising the drug and a
diketopiperazines diketopiperazine.

8. (original) The device of claim 7 wherein the device is a nasal insufflator.
9. (original) The device of claim 7 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.
10. (original) The device of claim 7 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.
11. (previously presented) The device of claim 7 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.
12. (previously presented) The device of claim 7 wherein the diketopiperazine diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.
13. (canceled)
14. (currently amended) A method of administering a drug to the nasal region of a patient in need thereof, comprising nasally administering a dry powder suitable for nasal administration,

AMENDMENT AND RESPONSE TO OFFICE ACTION

wherein the dry powder form comprises microparticles having an average a particle size of between 10 microns and to 20 microns in diameter and comprising the drug and a diketopiperazines diketopiperazine.

15. (original) The method of claim 14 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

16. (original) The method of claim 14 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

17. (previously presented) The method of claim 14 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.

18. (currently amended) The method of claim 14 wherein the diketopiperazine diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.

19. (canceled)

20. (previously presented) The composition of claim 1 formed by spray drying.

21. (previously presented) The device of claim 7 wherein the microparticles are formed by spray drying.